6 results
Primary objective;Confirm superiority of IgG antibody levels against pertussis toxin (Ptx), present in the acellular vaccines, in infants at the age of 3 months of mothers having received a pertussis vaccine during pregnancy versus infants of…
Currently, caplacizumab is being developed for treatment of acquired thrombotic thrombocytopenic purpura (TTP). TTP is a rare and potentially life-threatening thrombotic microangiopathy, in which accumulation of ULvWF multimers leads to an increased…
The main purpose of this study is to investigate the longitudinal effects of an aP booster vaccination in adults, on long-term humoral and cellular memory immunity against B. pertussis. By measuring antibody levels against the various pertussis…
*Premature infants and maternal pertussis immunization. Is second trimester vaccination beneficial?*
Our primary objective is to evaluate non-inferiority of anti-Pertussis Toxin (PT) IgG in term infants at 2m of age born of mothers having received a pertussis vaccine between 20-24w Gestational Age (GA) compared to a reference anti-PT IgG at 2m of…
This study is designed to dissect the immune response after Bp booster vaccination by investigating the kinetics of innate and adaptive immune cells, and detection and characterization of Bp-specific memory B cells and plasma cells.
The primary objective is to evaluate the efficacy of IFX-1 treatment as a replacement for glucocorticoids [GC] therapy in subjects with GPA and MPA.Secondary objectives:*To assess safety and tolerability of IFX-1*To compare GC-induced toxicity of…